Ep 40: John Jernigan & decolonization. A paper-based susceptibility test. A potential new Giardia treatment. AMR vaccines.
2022-08-01
Welcome back to the AMR studio after our short summer break! For this episode, we are bringing you an interview with Dr. John Jernigan, physician and director of the Office of Hospital Acquired Infections Prevention Research and Evaluation Division at the CDC. We talk with him about the new innovative approaches that the CDC is working on when it comes to AMR, with a focus on decolonization. Learn with us about why decolonization is important and how it can help the burden of AMR. In our news section, we cover a very recent publication that explores a new, simple, and cheap multiplexed test for antibiotic susceptibility, and a very interesting study published by one of our PhD students looking into new targets and treatment of Giardia intestinalis. Thank you for being with us in our 40th episode!
You can follow us and subscribe to our podcast to get new episodes directly in your preferred device and platform:
or you can listen to our 40th episode right here:
Relevant links:
- Dr. John Jerningan profile page at the CDC.
- Workshop Drug Development Considerations for the Prevention of Healthcare-Associated Infections with FDA on 30th of August 2022.
- CDC page on antibiotics and antimicrobial resistance.
- What CDC Is Doing: Investments & Action page.
- CDC page on microbial ecology.
Further Reading:
- Multiplexed paper-based assay for personalized antimicrobial susceptibility profiling of Carbapenem-resistant Enterobacterales performed in a rechargeable coffee mug. First article covered in the news.
- Giardia intestinalis thymidine kinase is a high-affinity enzyme crucial for DNA synthesis and an exploitable target for drug discovery. Second article covered in the news.
-
Bacterial vaccines in clinical and preclinical development 2021. WHO report covered in the news.
If you have any comments and suggestions you can email us here, or tweet to us (@UAC_UU) using the hashtag #theAMRStudio.